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The bioactive signalling lipid sphingosine-1-phosphate 
(S1P) was discovered over 25 years ago as a regulator 
of cell proliferation.  Since that time, S1P has been 
implicated across multiple cellular signalling systems, 
including cell survival, migration and differentiation. As 
a result, S1P has been associated with several health 
conditions and non-communicable diseases including 
cancer, inflammatory disorders, diabetes and athero-
sclerosis, much of which is attributed to its role in 
immune cell trafficking. S1P exerts its cellular effects 
through G-protein coupled receptors: S1P receptors 1-5 
(S1PR1-5) [1]. 
Levels of cellular S1P are modulated through the 
deacylation and phosphorylation of ceramide, the 
interconversion and subsequent ratio of these molecules 
is referred to as the S1P/ceramide axis. Many of the 
cellular signalling systems modulated by S1P are 
conversely affected by ceramide for example S1P pro-
motes growth and inhibits apoptosis whereas ceramide 
has the opposite effects on these processes [2]. 
More recently, an emerging role for the S1P/ceramide 
axis in the regulation of energy balance has been 
indicated in several studies. In 2014, Silva et al. 
demonstrated that S1P receptor 1 (S1PR1) was highly 
enriched in pro-opiomelanocortin (POMC) neurons in 
the hypothalamus of rats. The hypothalamus is a key 
sensor and regulator of nutrient signals [3] and POMC 
neurons in particular are involved in leptin signal 
transduction pathway and are thought to help signal 
satiety and inhibit feeding (anorexigenic). Silva et al. 
also found that S1P had an anorectic effect of rats, as 
intracerebroventricular (ICV) injections of S1P reduced 
food consumption and increased energy expenditure. 
The study also indicated that these changes were 
mediated through leptin signal transduction as S1P 
injection resulted in a dose-dependent increase in 
tyrosine phosphorylation of both Janus kinase 2 (Jak2) 
and signal transducer and activator of transcription 3 
(STAT3), signalling of which controls anorexigenic and 
thermogenic signalling in the hypothalamus. In 
addition, disruption of S1PR1 in the arcuate nucleus 
caused hyperphagia, low levels of STAT3 phosphoryla-
tion and reduced energy expenditure [4]. Further studies 
by the same group indicated that S1P is increased by 
exercise in the cerebrospinal fluid (CSF) of young rats, 
and transferring CSF from these rats into the 
hypothalamus of middle-aged rats reduced food intake.  








In addition, chronic exercise increased both S1PR1 and 
STAT3 phosphorylation in the hypothalamus of middle 
aged mice, mirroring previous effects seen upon ICV 
injection of S1P in rats. ICV injection of S1PR1 
activators also induced STAT3 phosphorylation in the 
hypothalamus and reduced food intake in middle aged 
rats [5].  
Da Silva also found that a high fat diet (HFD) resulting 
in obesity not only caused hypothalamic leptin resis-
tance but also decreased S1PR1 protein levels in both 
mice and rats [4]. This effect however has been shown 
to be reversible in male C57B/6J mice fed on a HFD 
that were injected intraperitoneally with S1P analogue 
FTY720, it blunted accumulation of large adipocytes, 
promoted lipolysis and inhibited adipogenesis. FTY720 
also decreased lipid accumulation in maturing preadipo-
cytes and down-regulated markers of adipogenic dif-
ferentiation. FTY720 also induces protein kinase B 
(Akt) phosphorylation, which is known to improve 
insulin sensitivity and reduce fat accumulation [6].  
Conversely, calorie restriction (CR) has also been 
shown to alter S1P levels, in our recent study mice 
undergoing calorie restriction (CR) showed a hepatic 
increase in S1P and sphingomyelin whilst ceramide was 
decreased. Furthermore, this response was dose depen-
dent, with the response becoming more pronounced 
with increasing CR (Figure 1). Similar to the effects 
seen in obese mice injected with S1P analogue FTY720, 
CR also produces a metabolic shift from lipogenesis to 
lipolysis, which may in part be attributed to changes in 
the S1P/ceramide axis [6,7]. In our study we found that 
S1P correlated negatively with body temperature and 
positively with food anticipatory activity, indicating that 
it may also have a role in the physical and behavioural 
changes associated with hunger [7]. However, intra-
peritoneal injections of S1P and an S1PR1 agonist were 
not effective in changing food intake or body tempera-
ture [7]. Unlike in the previous studies where direct ICV 
injection of S1P produced a response through the 
JAK/STAT pathway, our findings suggest that S1P may 
only act locally [4,5]. However, we only tested a limited 
dose range so this requires further investigation.  
Taken together, these findings suggest a significant role 
of the S1P/S1PR1 axis in the hypothalamus, adipose 
tissue and liver. In particular activation of hunger 
signalling pathways through S1P produces an anti-
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energy expenditure, increasing lipolysis, decreasing 
lipogenesis and food intake. The S1P/S1PR1/ceramide 
axis, in addition to downstream signalling pathways, 
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studies provide insight into how S1P analogues may be 
used as a therapeutic agent in the treatment of obesity, 
and the importance of further work to understand the 
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